Literature DB >> 28325190

Neuroendocrine Tumors of the Stomach.

Britney Corey1, Herbert Chen2.   

Abstract

Gastric neuroendocrine tumors (NETs) are classified into three types. Type I gastric NETs are associated with chronic atrophic gastritis. They have a good prognosis and endoscopic resection is the mainstay of treatment. Type II gastric NETs are caused by hypergastrinemia. They have a poorer prognosis, and resection is required to control the disease. Endoscopic versus surgical resection is recommended for the gastric lesion. Type III gastric NETs are sporadic and not associated with any specific condition. They have the worst prognosis with the highest rate of metastatic disease, and oncologic resection is recommended. Medical therapies have some role. Published by Elsevier Inc.

Entities:  

Keywords:  Chronic atrophic gastritis; Gastric carcinoid; Gastric neuroendocrine tumor; Sporadic carcinoid; Zollinger-Ellison syndrome

Mesh：

Year:  2017        PMID： 28325190     DOI： 10.1016/j.suc.2016.11.008

Source DB:  PubMed          Journal:  Surg Clin North Am        ISSN： 0039-6109            Impact factor:   2.741


  8 in total

Review 1.  Clinical aspects of multiple endocrine neoplasia type 1.

Authors:  Abdallah Al-Salameh; Guillaume Cadiot; Alain Calender; Pierre Goudet; Philippe Chanson
Journal:  Nat Rev Endocrinol       Date:  2021-02-09       Impact factor: 43.330

2.  SSAT State-of-the-Art Conference: Current Surgical Management of Gastric Tumors.

Authors:  Jeffrey A Norton; Teresa Kim; Joseph Kim; Martin D McCarter; Kaitlyn J Kelly; Joyce Wong; Jason K Sicklick
Journal:  J Gastrointest Surg       Date:  2017-08-14       Impact factor: 3.452

Review 3.  Gastric neuroendocrine neoplasms: a primer for radiologists.

Authors:  Molly E Roseland; Isaac R Francis; Kimberly L Shampain; Erica B Stein; Ashish P Wasnik; John D Millet
Journal:  Abdom Radiol (NY)       Date:  2022-04-12

4.  Gastric pyloric gland adenoma resembling a submucosal tumor: A case report.

Authors:  Cong-Cong Min; Jun Wu; Feng Hou; Tao Mao; Xiao-Yu Li; Xue-Li Ding; Hua Liu
Journal:  World J Clin Cases       Date:  2020-06-06       Impact factor: 1.337

5.  CDK5RAP3 inhibits angiogenesis in gastric neuroendocrine carcinoma by modulating AKT/HIF-1α/VEGFA signaling.

Authors:  Jian-Xian Lin; Xiong-Feng Weng; Xin-Sheng Xie; Ning-Zi Lian; Sheng-Liang Qiu; Jia-Bin Wang; Jun Lu; Qi-Yue Chen; Long-Long Cao; Mi Lin; Ru-Hong Tu; Ying-Hong Yang; Si-Jia Liu; Min Hu; Yi-Ke Lin; Chang-Ming Huang; Chao-Hui Zheng; Ping Li; Jian-Wei Xie
Journal:  Cancer Cell Int       Date:  2019-11-07       Impact factor: 5.722

6.  A Prospective and Retrospective Clinical Controlled Observation of Chinese Herbal Decoction (SMLJ01) for Type 1 Gastric Neuroendocrine Tumors.

Authors:  Yingying Chen; Deng Han; Jiqing Zhu; Jie Chen; Haiyi Hu; Dou Dou; Xin Wang; Bing Yuan; Chao Wang; Zhirong Qi; Xinran Zhang; Jixi Liu; Jie Luo; Huangying Tan
Journal:  Integr Cancer Ther       Date:  2020 Jan-Dec       Impact factor: 3.279

7.  Risk factors for lymph node metastasis in gastric neuroendocrine tumor: a retrospective study.

Authors:  Xianghui Li; Lihua Shao; Xiaofeng Lu; Zhengyang Yang; Shichao Ai; Feng Sun; Meng Wang; Wenxian Guan; Song Liu
Journal:  BMC Surg       Date:  2021-03-31       Impact factor: 2.102

Review 8.  Gastric neuroendocrine neoplasms and precursor lesions: Case reports and literature review.

Authors:  Alina Boeriu; Daniela Dobru; Crina Fofiu; Olga Brusnic; Danusia Onişor; Simona Mocan
Journal:  Medicine (Baltimore)       Date:  2022-01-14       Impact factor: 1.817
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.